|
DTIL | Precision Biosciences Inc |
|
|
DTIL | Precision Biosciences Inc |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.03 |
| Leverage | 82.21% |
| Market Cap | $ 537.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -83.4m |
| Margin | -1401.41% |
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.